首页 | 本学科首页   官方微博 | 高级检索  
     

甲氰咪胍影响非酒精性脂肪性肝炎大鼠血糖、胰岛素等指标的实验研究
引用本文:徐辉,闻勤生,王旭霞,张亚飞,李军,顾柄权. 甲氰咪胍影响非酒精性脂肪性肝炎大鼠血糖、胰岛素等指标的实验研究[J]. 临床肝胆病杂志, 2007, 23(2): 112-114
作者姓名:徐辉  闻勤生  王旭霞  张亚飞  李军  顾柄权
作者单位:第四军医大学唐都医院,消化科,陕西,西安,710038;第四军医大学唐都医院,传染科,陕西,西安,710038;第四军医大学唐都医院,检验科,陕西,西安,710038
基金项目:陕西省自然科学研究计划项目资助(编号2003C2035)
摘    要:探讨非酒精性脂肪性肝炎(NASH)大鼠经甲氰咪胍治疗后肝微粒体CYP450、CYP2E1含量、血糖、胰岛素等指标的变化.将30只雄性SD大鼠随机分为对照组(n=10)、模型组(n=10)和治疗组(n=10),治疗组给予甲氰咪胍200 mg·kg^-1·d^-1灌胃,饲养12周,分别于实验第4、6、8、10、12周采用剪尾取血法取血,前四次取血测定血糖、AST、ALT含量,最后一次处死大鼠后取血测定血糖、胰岛素、肝功、血脂、CYP450及CYP2E1含量,观察肝组织学特点.观察到模型组大鼠肝功、血糖指标升高,并随实验进展更加明显;治疗组CYP450、CYP2E1、ALT、AST含量均低于模型组(P<0.05),且大鼠的肝细胞损害明显减轻,但其余指标无显著差异.可见甲氰咪胍能够减轻NASH大鼠肝细胞损害,抑制CYP450、CYP2E1表达,改善肝功水平,不能改善胰岛素抵抗,及降低血糖、血脂.

关 键 词:甲氰咪胍  非酒精性脂肪性肝炎  细胞色素P450  胰岛素抵抗  肝功  血脂
文章编号:1001-5256(2007)02-0112-03
收稿时间:2006-01-18
修稿时间:2006-03-28

The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats
XU Hui, WEN Qin - sheng, WANG Xu -xia,et al.. The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats[J]. Chinese Journal of Clinical Hepatology, 2007, 23(2): 112-114
Authors:XU Hui   WEN Qin - sheng   WANG Xu -xia  et al.
Affiliation:XU Hui, WEN Qin - sheng, WANG Xu -xia, et al.
Abstract:To study the effect of cimetidine on cytochrome P450,CYP2E1,blood sugar,insulin and othert indexes in nonalcoholic steatohepatitis(NASH) rats.30 male SD rats were randomly divided into three groups,control group(n=10),model group(n=10) and therapeutic group(n=10).The therapeutic group received cimetidine 200mg daily for 12 weeks.The rats were taken the blood by cutting tails at the 4th,6th,8th,10th and 12th weeks during the study.In the first 4 times,the level of serum AST,ALT and blood sugar was measured.And at the last time,CYP450,CYP2E1,blood sugar,insulin,ALT,AST,TG,TC,LDL,and HDL were measured.We also observe the histologic characters of NASH rats.We observed the levels of ALT,AST,blood sugar in model group increased significantly,then kept increasing through the study.The decrease of CYP450,CYP2E1 in therapeutic groups was obvious.There was an obvious difference of ALT,AST between therapeutic group and model group,while the other indexes be not obviously distinguished from each other.The hepatic injury in therapeutic groups was significantly lessened.So cimetidine can prevent nonalcoholic hepatic injury,inhibit the expressions of CYP450 and CYP2E1,and decrease the expression of ALT and AST,but have no effect on blood sugar,insulin,TG,TC and lipoprotein.
Keywords:cimitidine    nonalcoholic steatohepatitis   cytochrome P450    insulin resistance   hepatic function   blood fat
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号